Close
Almac
Achema middle east

Medicines Discovery Catapult helping advance Covid-19 testing

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Next-Generation Laboratory Equipment Redefining Drug Discovery Workflows

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.
- Advertisement -

The Medicines Discovery Catapult will open a new dedicated laboratory at Bruntwood SciTech’s Alderley Park in Cheshire, making it one of the government’s national hubs for Covid-19 testing.

Medicines Discovery Catapult is also helping to co-ordinate the establishment of the UK’s new hub laboratories being developed in Milton Keynes and Glasgow.

The hubs are being created to help deliver Covid-19 testing at advanced rates with the potential of allowing uninfected frontline staff to return to work.

The Medicines Discovery Catapult has worked with a range of UK expertise including academia, NHS, biotech and industry to deliver its testing facility. Universities, research institutes and commercial companies across Britain are lending their testing equipment to the new hub laboratories.

The laboratory at Alderley Park will receive samples from across the UK to be tested for Covid-19 – with the facility reportedly running around the clock.

Professor Chris Molloy, chief executive officer at Medicines Discovery Catapult said: “At a time of national challenge, harnessing the great strengths of the UK’s businesses, universities, the NHS and research institutes requires expert teams working to a common purpose.

“The immense effort by so many partners to establish these national hub laboratories will provide vital information on the level of Covid-19 infection across the UK. It also demonstrates innovative medical science being delivered at scale.

“At Medicines Discovery Catapult, we are well placed to lead the establishment of the hub laboratory at Alderley park bringing together the scientific, clinical and industrial know-how from many organisations – engaging a skilled local workforce – to support increased capacity Covid-19 testing.”

Dr Kath Mackay, managing director of Bruntwood SciTech – Alderley Park added:“At Alderley Park we have the infrastructure and network of expertise that the Medicines Discovery Catapult needs to launch this critical facility, and we are proud to be working together with the wider science community on such a vitally important project.”

Latest stories

Related stories

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Next-Generation Laboratory Equipment Redefining Drug Discovery Workflows

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »